Deals, Partnering

Opko Health acquires lead NK-1 compounds from Schering-Plough

Posted on 13 October 2009

Phase 1 clinical testing has also been initiated for a second compound in the same class. It is anticipated that these compounds may have advantages over presently marketed products.

Print Friendly, PDF & Email

Leave a Reply

 

cpbannerad300x150new2gif
rauconbadgejpg
e78banner300x150animgif
cpbannerad300x150new2gif
rauconbadgejpg
e78banner300x150animgif